Ajanta Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 17, 2025
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajanta Pharma held its 46th Annual General Meeting on July 17, 2025, at 11:00 a.m. via Video Conferencing. Six resolutions were voted on and all passed with the required majority. The resolutions covered adoption of audited financial statements for FY ending March 31, 2025 (99.96% in favor), confirmation of the interim dividend (99.9999% in favor), reappointment of Mr. Rajesh Mannalal Agrawal as Director retiring by rotation (99.04% in favor), reappointment of Mr. Madhusudan B. Agrawal as Executive Director and Vice-Chairman via special resolution (97.63% in favor), appointment of M/s D.G. Prajapati & Associates as Secretarial Auditors (99.91% in favor), and ratification of Cost Auditor remuneration for FY2025-26 (99.9997% in favor). Voting was conducted through remote e-voting (NSDL platform) and e-voting during the AGM, with Pramod S. Shah & Associates serving as the Scrutinizer. The highest dissent of 2.37% came from public institutions on the reappointment of Mr. Madhusudan B. Agrawal.
All AGM resolutions were approved with strong shareholder support, indicating broad confidence in company management. The interim dividend was formally confirmed by shareholders. No material negative signals emerged, though the modestly lower support for the Executive Director's reappointment is routine and not concerning.